Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Carbonic anhydrase IX is overexpressed in many solid tumors including hypoxic tumors and is a potential target for cancer therapy and diagnosis. Reported imaging agents targeting CA-IX are successful mostly in clear cell renal carcinoma as SKRC-52 and no candidate was approved yet in clinical trials for imaging of CA-IX. To validate CA-IX as a valid target for imaging of hypoxic tumor, we designed and synthesized novel [F]-PET tracer (1) based on acetazolamide which is one of the well-known CA-IX inhibitors and performed imaging study in CA-IX expressing hypoxic tumor model as 4T1 and HT-29 in vivo models other than SKRC-52. [F]-acetazolamide (1) was found to be insufficient for the specific accumulation in CA-IX expressing tumor. This study might be useful to understand in vivo behavior of acetazolamide PET tracer and can contribute to the development of successful PET imaging agents targeting CA-IX in future. Additional study is needed to understand the mechanism of poor targeting of CA-IX, as if CA-IX is not reliable as a sole target for imaging of CA-IX expressing hypoxic solid tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2018.01.060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design and Synthesis of New Multi-Target Coumarin Analogues Acting as Carbonic Anhydrases IX/XII and Topoisomerase II Inhibitors With Apoptotic Potential.
Arch Pharm (Weinheim)
September 2025
Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Through applying the hybridization technique, new coumarin derivatives (2-17) were prepared with substitution at coumarin C-3 utilizing various heterocyclic derivatives, aiming to afford multi-target carbonic anhydrases (CAs) IX/XII and topoisomerase II (Topo II) inhibitors with potent antiproliferative activity. Eight different cell lines were used to evaluate the growth inhibition percentages (GI%) of cancer cells determined by coumarin analogues 1-17. Analogues 16 and 17 had the most substantial cytotoxic effects, achieving mean GI% of 86.
View Article and Find Full Text PDFDual inhibition of carbonic anhydrase IX and glutathione peroxidase 4 as a novel strategy for ferroptosis-induced tumor cell death.
Eur J Med Chem
September 2025
NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, Florence, 50019, Italy. Electronic address:
In this study, we explored a dual-target strategy combining the inhibition of human carbonic anhydrase IX (hCA IX), a tumor-associated isoform, and glutathione peroxidase 4 (GPX4), a key regulator of ferroptosis. We demonstrated that the simultaneous inhibition of hCA IX and GPX4 disrupts redox and iron homeostasis, thereby enhancing cell death via ferroptosis. Three series of compounds were rationally designed and synthesized based on the ML162 scaffold using an integrated structural approach and their enzymatic inhibition was evaluated in vitro.
View Article and Find Full Text PDFDesign, anticancer activity, and mechanistic evaluation of a novel class of selective human carbonic anhydrase IX inhibitors featuring a trifluorodihydroxypropanone pharmacophore.
Eur J Med Chem
November 2025
Department of Medicine, Surgery and Pharmacy, University of Sassari, Via Vienna 2, 07100, Sassari, Italy. Electronic address:
Carbonic anhydrases (CAs) have emerged as promising drug targets for cancer therapy. In particular, the human (h) CA IX (hCA IX) isoform is expressed in a wide variety of malignancies and appears tightly regulated by micro-environmental hypoxia. Ongoing efforts aim to identify novel classes of selective CA inhibitors (CAIs) by exploring molecular diversity and discovering original chemotypes and pharmacophores.
View Article and Find Full Text PDFAn ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo.
Exp Hematol Oncol
August 2025
Department of Molecular and Translational Medicine, University of Brescia, Brescia, 25123, Italy.
Carbonic anhydrase IX (CA IX) is a tumor-specific metallo-enzyme upregulated during hypoxic conditions and implicated in several pathophysiological processes where tissue pH regulation is required such as cancer, cell invasion, metastatic and stem-like features, drug resistance and recurrence. Indeed, CA IX expression has been correlated with poor prognosis, aggressiveness and disease progression in several solid tumors, and its targeting has been proposed as a therapeutic approach to treat aggressive cancers. To date, several CA IX targeting approaches have been developed to inhibit its activity in neoplastic tissues including the clinical grade (Phase Ib/II) ureido-substituted benzenesulfonamide SLC-0111, which has been widely investigated over the past years.
View Article and Find Full Text PDFCarbonic Anhydrase IX Induces Human Osteosarcoma Cell Metastasis by Activating HSPA6 Expression Through the AMPK Signalling Pathway.
J Cell Mol Med
August 2025
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
Osteosarcoma(OS), the most common primary bone cancer, has high metastatic potential and a high mortality rate. Carbonic anhydrase IX (CAIX), a hypoxia-induced transmembrane protein, is highly expressed in numerous cancers. Over the past decades, scientists have made extensive efforts to determine the role of CAIX in various cancers.
View Article and Find Full Text PDF